Safety, tolerability, efficacy and dose-response of GSK2831781 in patients with active Ulcerative Colitis.
THE RECRUITMENT FOR THIS STUDY IS SUSPENDED DURING THE CORONAVIRUS OUTBREAK.
Thank you for your interest in this study – this page will be updated when it is re-open for recruiting. In the meantime, please see other opportunities to take part here and follow us on Twitter for the latest updates.
Investigators at research sites in Addenbrooke’s Hospital in Cambridge, John Radcliffe Hospital in Oxford and St Helen’s and Knowsley Hospitals NHS Trust in Prescot are looking for patients with active Ulcerative Colitis to take part in a study to evaluate the safety, tolerability, efficacy and dose-response of a new investigational drug called GSK2831781.
GSK2831781 targets a specific type of cell that is part of the immune system which, if overactive, can contribute to inflammation in the body. The particular cells targeted by GSK2831781 are found in higher numbers in areas of the gut where there is inflammation in patients with Ulcerative Colitis. These cells may be contributing to the disease, and GSK2831781 is designed to selectively remove them.
This new study, funded by GlaxoSmithKline, will seek to answer the following questions:
- Is GSK2831781 safe?
- How well does GSK2831781 work to treat people with ulcerative colitis?
- What dose of GSK2831781 is most appropriate?
If you need to travel to reach one of these treatment sites, your costs will be reimbursed. You will need to be over 18 to take part and have moderate-to-severe symptoms of ulcerative colitis. This study is not open to people with Crohn's disease.
This research study is NOT funded or organised by Crohn's & Colitis UK and, therefore, we cannot take responsibility for your involvement in the research. It is a patient’s choice to take part.